This summary was created by AI, based on 5 opinions in the last 12 months.
Regeneron Pharmaceuticals Inc. (REGN-Q) has faced a significant decline in its market cap, leading some experts to view the current situation as a buying opportunity due to an overreaction in selling. The company's long-term trajectory is bolstered by a strong CEO and a promising pipeline of drugs, including a candidate for weight-loss treatments that is still in early testing phases. Despite facing bad news recently, experts believe the company's fundamentals remain intact for long-term investors. Key drugs such as Eylea and Dupixent are driving sales, with Eylea generating substantial revenues even as it faces competition and an impending patent expiration. REGN's valuation, trading at 22x forward PE with a share buyback plan in place, further reinforces the optimism surrounding its prospects.
He's bullish pharmas if the economy weakens. He likes it for growing organically, not buying companies, and in developing its drugs in-house or with partners. Their drug pipeline overcomes worries of their existing drugs coming off patent. Their key drug, Eylea, topped $1.04 billion in Q1 and $5.89 billion in full-year US net sales. But Roche has released a rival drug, while Eylea will come off patent in a couple years as they successfully protect their patent in court. Also, REGN just developed a new version of Eylea. Dupixent is their second-biggest drug and is performing well as well. Despite its growth, REGN trades at only 22x forward PE, and announced a $3 billion share buyback.
Regeneron Pharmaceuticals Inc is a American stock, trading under the symbol REGN-Q on the NASDAQ (REGN). It is usually referred to as NASDAQ:REGN or REGN-Q
In the last year, 4 stock analysts published opinions about REGN-Q. 4 analysts recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc was recommended as a Top Pick by on . Read the latest stock experts ratings for Regeneron Pharmaceuticals Inc.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
4 stock analysts on Stockchase covered Regeneron Pharmaceuticals Inc In the last year. It is a trending stock that is worth watching.
On 2025-04-15, Regeneron Pharmaceuticals Inc (REGN-Q) stock closed at a price of $563.07.
It's lost a third of its market cap and the selling is overdone. Now, is a buying opportunity.